[
  {
    "generic_name": "Buprenorphine",
    "brand_names": ["Subutex", "Suboxone", "Buvidal"],
    "active_ingredients": "Buprenorphine HCl 2mg",
    "nafdac_approved": true,
    "nafdac_registration_number": "A4-9020",
    "nafdac_schedule": "schedule_2",
    "nafdac_schedule_date": "2008-01-01",
    "us_dea_schedule": "Schedule III",
    "uk_controlled_drug_class": "Class C",
    "who_essential_medicine": true,
    "requires_special_prescription": true,
    "requires_physician_only": true,
    "pharmacist_can_prescribe": false,
    "maximum_days_supply": 30,
    "requires_photo_id": true,
    "therapeutic_class": "Opioid Analgesic/Addiction Treatment",
    "pharmacological_class": "Partial Opioid Agonist",
    "mechanism_of_action": "Partial mu-opioid receptor agonist, kappa-opioid receptor antagonist",
    "is_controlled": true,
    "is_high_risk": true,
    "requires_monitoring": true,
    "monitoring_type": "Pain control, Respiratory function, Liver function, Addiction management",
    "monitoring_frequency_days": 30,
    "addiction_risk": true,
    "abuse_potential": "moderate",
    "minimum_age": 16,
    "maximum_age": null,
    "pregnancy_category": "C",
    "breastfeeding_safe": false,
    "major_contraindications": ["Severe respiratory depression", "Acute alcoholism", "Delirium tremens", "Severe hepatic impairment"],
    "allergy_cross_reactions": ["Other opioids"],
    "black_box_warning": true,
    "black_box_warning_text": "Risk of respiratory depression especially when used IV, hepatotoxicity, risk of misuse/abuse/addiction, neonatal opioid withdrawal syndrome, requires special prescriber certification for addiction treatment",
    "major_drug_interactions": ["Benzodiazepines (fatal respiratory depression)", "CNS depressants (sedation)", "CYP3A4 inhibitors (increased levels)", "Naltrexone (precipitates withdrawal)"],
    "food_interactions": "Avoid alcohol, grapefruit juice may increase levels",
    "search_keywords": ["buprenorphine", "subutex", "suboxone", "opioid addiction", "maintenance therapy", "partial agonist"],
    "generic_variations": ["Buprenorphine Hydrochloride", "Buprenorphine/Naloxone combination"],
    "common_misspellings": ["Buprenorphin", "Buprenorfine", "Subutex"],
    "safer_alternatives": ["Methadone (full agonist, more overdose risk)", "Naltrexone (no opioid effects)"],
    "cheaper_alternatives": ["Methadone"],
    "notes": "Partial opioid agonist used for chronic pain and opioid addiction treatment. Ceiling effect on respiratory depression makes it safer than full agonists. Long duration of action (24-72 hours). Requires special training/certification for prescribing in addiction treatment. Lower abuse potential than full agonists but still controlled.",
    "is_active": true
  },
  {
    "generic_name": "Pentazocine",
    "brand_names": ["Fortral", "Talwin", "Fortwin"],
    "active_ingredients": "Pentazocine Lactate 30mg",
    "nafdac_approved": true,
    "nafdac_registration_number": "A4-9021",
    "nafdac_schedule": "schedule_2",
    "nafdac_schedule_date": "2008-01-01",
    "us_dea_schedule": "Schedule IV",
    "uk_controlled_drug_class": "Class C",
    "who_essential_medicine": false,
    "requires_special_prescription": true,
    "requires_physician_only": true,
    "pharmacist_can_prescribe": false,
    "maximum_days_supply": 7,
    "requires_photo_id": true,
    "therapeutic_class": "Opioid Analgesic",
    "pharmacological_class": "Mixed Opioid Agonist-Antagonist",
    "mechanism_of_action": "Kappa-opioid receptor agonist, weak mu-opioid antagonist",
    "is_controlled": true,
    "is_high_risk": true,
    "requires_monitoring": true,
    "monitoring_type": "Pain level, Respiratory function, Psychotomimetic effects, Blood pressure",
    "monitoring_frequency_days": 7,
    "addiction_risk": true,
    "abuse_potential": "moderate",
    "minimum_age": 18,
    "maximum_age": null,
    "pregnancy_category": "C",
    "breastfeeding_safe": false,
    "major_contraindications": ["Respiratory depression", "Acute MI (increases cardiac workload)", "Head injury with increased ICP"],
    "allergy_cross_reactions": ["Other opioids"],
    "black_box_warning": false,
    "black_box_warning_text": "",
    "major_drug_interactions": ["Other opioids (may precipitate withdrawal)", "CNS depressants (respiratory depression)", "Tobacco smoking (increased metabolism)"],
    "food_interactions": "Avoid alcohol",
    "search_keywords": ["pentazocine", "fortral", "talwin", "mixed agonist-antagonist", "moderate pain"],
    "generic_variations": ["Pentazocine Lactate", "Pentazocine Hydrochloride"],
    "common_misspellings": ["Pentazocin", "Pentazosine", "Fortrall"],
    "safer_alternatives": ["Tramadol (weaker)", "NSAIDs for moderate pain"],
    "cheaper_alternatives": ["Tramadol", "Codeine"],
    "notes": "Mixed opioid agonist-antagonist. Can precipitate withdrawal in opioid-dependent patients. May cause psychotomimetic effects (hallucinations, dysphoria) at higher doses. Increases blood pressure and cardiac workload. Less respiratory depression than pure agonists. Was heavily abused IV in combination with antihistamines (T's and Blues) in 1980s, leading to reformulation with naloxone.",
    "is_active": true
  },
  {
    "generic_name": "Hydromorphone",
    "brand_names": ["Dilaudid", "Exalgo", "Palladone"],
    "active_ingredients": "Hydromorphone HCl 2mg",
    "nafdac_approved": true,
    "nafdac_registration_number": "A4-9022",
    "nafdac_schedule": "schedule_2",
    "nafdac_schedule_date": "2005-01-01",
    "us_dea_schedule": "Schedule II",
    "uk_controlled_drug_class": "Class A",
    "who_essential_medicine": false,
    "requires_special_prescription": true,
    "requires_physician_only": true,
    "pharmacist_can_prescribe": false,
    "maximum_days_supply": 3,
    "requires_photo_id": true,
    "therapeutic_class": "Opioid Analgesic",
    "pharmacological_class": "Semisynthetic Opioid",
    "mechanism_of_action": "Potent mu-opioid receptor agonist",
    "is_controlled": true,
    "is_high_risk": true,
    "requires_monitoring": true,
    "monitoring_type": "Pain control, Respiratory rate, Sedation level, Addiction signs",
    "monitoring_frequency_days": 1,
    "addiction_risk": true,
    "abuse_potential": "severe",
    "minimum_age": 18,
    "maximum_age": null,
    "pregnancy_category": "C",
    "breastfeeding_safe": false,
    "major_contraindications": ["Respiratory depression", "Acute asthma", "Paralytic ileus", "Known hypersensitivity"],
    "allergy_cross_reactions": ["Other opioids", "Morphine", "Codeine"],
    "black_box_warning": true,
    "black_box_warning_text": "High risk of fatal respiratory depression, extreme addiction potential, 5-8x more potent than morphine, accidental exposure can be fatal especially in children",
    "major_drug_interactions": ["CNS depressants (fatal respiratory depression)", "MAOIs", "Benzodiazepines (respiratory depression)", "Alcohol (fatal)", "CYP3A4 inhibitors"],
    "food_interactions": "Avoid alcohol completely",
    "search_keywords": ["hydromorphone", "dilaudid", "opioid", "severe pain", "cancer pain", "potent analgesic"],
    "generic_variations": ["Hydromorphone Hydrochloride"],
    "common_misspellings": ["Hydromorphon", "Dilauded", "Diluadid"],
    "safer_alternatives": ["Morphine (less potent)", "Oxycodone"],
    "cheaper_alternatives": ["Morphine"],
    "notes": "Highly potent semisynthetic opioid. 5-8x more potent than morphine. Used for severe acute and cancer pain. Rapid onset when IV (5-15 minutes). High euphoric effect increases abuse potential. Often diverted and abused. Available in immediate and extended-release formulations. Requires careful dose conversion from other opioids.",
    "is_active": true
  },
  {
    "generic_name": "Phenobarbital",
    "brand_names": ["Luminal", "Phenobarbitone", "Gardenal"],
    "active_ingredients": "Phenobarbital Sodium 60mg",
    "nafdac_approved": true,
    "nafdac_registration_number": "A4-7835",
    "nafdac_schedule": "schedule_3",
    "nafdac_schedule_date": "2008-01-01",
    "us_dea_schedule": "Schedule IV",
    "uk_controlled_drug_class": "Class B",
    "who_essential_medicine": true,
    "requires_special_prescription": false,
    "requires_physician_only": true,
    "pharmacist_can_prescribe": false,
    "maximum_days_supply": 90,
    "requires_photo_id": false,
    "therapeutic_class": "Barbiturate",
    "pharmacological_class": "Anticonvulsant/Sedative-Hypnotic",
    "mechanism_of_action": "GABA-A receptor positive modulator, enhances inhibitory neurotransmission",
    "is_controlled": true,
    "is_high_risk": true,
    "requires_monitoring": true,
    "monitoring_type": "Seizure control, Serum drug levels, Liver function, Cognitive function, Suicidal ideation",
    "monitoring_frequency_days": 90,
    "addiction_risk": true,
    "abuse_potential": "moderate",
    "minimum_age": null,
    "maximum_age": null,
    "pregnancy_category": "D",
    "breastfeeding_safe": false,
    "major_contraindications": ["Porphyria", "Severe respiratory insufficiency", "Severe hepatic impairment", "History of barbiturate addiction"],
    "allergy_cross_reactions": ["Other barbiturates"],
    "black_box_warning": true,
    "black_box_warning_text": "Increased risk of suicidal thoughts and behavior. Physical dependence and severe withdrawal syndrome including seizures and death. Respiratory depression when combined with other CNS depressants.",
    "major_drug_interactions": ["Warfarin (decreased effect)", "Oral contraceptives (decreased effectiveness)", "Many drugs metabolized by CYP450 (inducer)", "CNS depressants (respiratory depression)", "Alcohol (severe CNS depression)"],
    "food_interactions": "Avoid alcohol, take with food to reduce GI upset",
    "search_keywords": ["phenobarbital", "luminal", "epilepsy", "seizures", "barbiturate", "anticonvulsant"],
    "generic_variations": ["Phenobarbital Sodium", "Phenobarbitone"],
    "common_misspellings": ["Phenobarbitol", "Phenobarbitall", "Luminal"],
    "safer_alternatives": ["Valproate", "Levetiracetam", "Lamotrigine", "Carbamazepine"],
    "cheaper_alternatives": ["Phenytoin"],
    "notes": "Long-acting barbiturate anticonvulsant. WHO Essential Medicine for epilepsy, especially in resource-limited settings. Very long half-life (80-120 hours). Strong CYP450 inducer affecting many drugs. Causes cognitive impairment, sedation. Discontinuation must be very gradual to prevent withdrawal seizures. Still widely used in Nigeria due to low cost.",
    "is_active": true
  },
  {
    "generic_name": "Thiopental",
    "brand_names": ["Pentothal", "Thiopentone", "Trapanal"],
    "active_ingredients": "Thiopental Sodium 500mg",
    "nafdac_approved": true,
    "nafdac_registration_number": "A4-7836",
    "nafdac_schedule": "schedule_3",
    "nafdac_schedule_date": "2010-01-01",
    "us_dea_schedule": "Schedule III",
    "uk_controlled_drug_class": "Class B",
    "who_essential_medicine": false,
    "requires_special_prescription": false,
    "requires_physician_only": true,
    "pharmacist_can_prescribe": false,
    "maximum_days_supply": 1,
    "requires_photo_id": false,
    "therapeutic_class": "Barbiturate",
    "pharmacological_class": "General Anesthetic/Anticonvulsant",
    "mechanism_of_action": "GABA-A receptor positive modulator, CNS depressant",
    "is_controlled": true,
    "is_high_risk": true,
    "requires_monitoring": true,
    "monitoring_type": "Blood pressure, Respiratory rate, Heart rate, Oxygen saturation, Level of consciousness",
    "monitoring_frequency_days": 1,
    "addiction_risk": false,
    "abuse_potential": "low",
    "minimum_age": null,
    "maximum_age": null,
    "pregnancy_category": "C",
    "breastfeeding_safe": false,
    "major_contraindications": ["Porphyria (absolute)", "Severe cardiovascular disease", "Status asthmaticus", "No IV access"],
    "allergy_cross_reactions": ["Other barbiturates", "Sulfites (in some formulations)"],
    "black_box_warning": true,
    "black_box_warning_text": "For use only by trained anesthesia providers. Risk of severe respiratory depression and cardiovascular collapse. Resuscitation equipment must be immediately available. Extravasation causes severe tissue necrosis. Intra-arterial injection causes severe arterial spasm and gangrene.",
    "major_drug_interactions": ["CNS depressants (enhanced effect)", "Cardiovascular drugs (hypotension)", "Opioids (respiratory depression)"],
    "food_interactions": "Not applicable (IV only, anesthesia)",
    "search_keywords": ["thiopental", "pentothal", "anesthesia", "barbiturate", "induction agent", "status epilepticus"],
    "generic_variations": ["Thiopental Sodium", "Thiopentone Sodium"],
    "common_misspellings": ["Thiopentol", "Thiopenthal", "Pentathol"],
    "safer_alternatives": ["Propofol (safer hemodynamically)", "Etomidate", "Ketamine"],
    "cheaper_alternatives": ["Ketamine (in resource-limited settings)"],
    "notes": "Ultra-short-acting IV barbiturate anesthetic. Rapid onset (30-60 seconds), brief duration (5-10 minutes). Historically 'truth serum' (unreliable). Used for anesthesia induction, status epilepticus, increased ICP management. Causes severe cardiovascular depression. Extravasation causes tissue necrosis. Intra-arterial injection can cause gangrene. Requires trained anesthesia provider. Hospital use only.",
    "is_active": true
  }
]
